SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Deel strikes multi-year deal with Arsenal as tech firm enters global sport

Jensen Huang’s quiet role emerges as Argamani describes Nvidia’s two-year vigil for Avinatan Or

Freed Nvidia engineer Avinatan Or meets Jensen Huang at U.S. headquarters

Palo Alto Networks: Hamas-linked hackers launch stealth espionage push across Arab governments

Buzz

Most popular

Daily

Weekly

1

Oracle’s stock has fallen 40% since Safra Catz announced her exit. Its latest earnings didn’t calm investors.

2

Freed Nvidia engineer Avinatan Or meets Jensen Huang at U.S. headquarters

3

After over $390 million in funding, Believer Meats abruptly shuts down

4

Breaking down the resurgence of M&As in times of economic uncertainty

5

Quantum Art raises $100 million Series A to scale full-stack quantum systems

Kare Schultz

6 stories about Kare Schultz

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman

The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations

ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman

Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines

מפעל טבע טק נאות חובב פיטורים

Teva in talks with Covid-19 vaccine manufacturers to co-produce shots

10.02.21|Reuters and CTech

"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO

קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

Teva beats analysts predictions with increased revenues from growth drivers

10.02.21|Sophie Shulman

The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020

מנכ"ל טבע החדש קור שולץ

Generic Drugmaker Teva Says Profit Will Continue to Drop in 2018

08.02.18|Dror Reich

Israel’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market

מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility